Romain GRIFFIER

Romain GRIFFIER

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
GBGabriel A. Brat
Gabriel A. Brat
GWGriffin M. Weber
Griffin M. Weber
NGNils Gehlenborg
Nils Gehlenborg
PAPaul Avillach
Paul Avillach
NPNathan P. Palmer
Nathan P. Palmer
IKIsaac S. Kohane
Isaac S. Kohane
We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across five countries (www.covidclinical.net). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions.

1 May 2019 in Radiology
Verified
Journal Article
Closed access
PLPierre Antoine Linck
Pierre Antoine Linck
GKGregory Kuchcinski
Gregory Kuchcinski
FMFanny Munsch
Fanny Munsch
RGRomain GRIFFIER
Romain GRIFFIER
RLRenaud Lopes
Renaud Lopes
TTThomas Tourdias
Thomas Tourdias
High iron content of the substantia nigra remote from supratentorial infarcts was associated with worse long-term motor function after stroke. BackgroundThe substantia nigra (SN) is suspected to be affected after remote infarction, in view of its large array of connections with the supratentorial brain. Whether secondary involvement of SN worsens overall clinical outcome after a supratentorial stroke has not previously been studied.PurposeTo assess longitudinal changes in SN R2* by using MRI in the setting of ipsilesional supratentorial infarct and the relationship of SN signal change to clinical outcome.Materials and MethodsParticipants prospectively included from 2012 to 2015 were evaluated at 24–72 hours (baseline visit) and at 1 year with MRI to quantify R2*. The SN was segmented bilaterally to calculate an R2* asymmetry index (SN-AI); greater SN-AI indicated greater relative R2* in the ipsilateral compared with contralateral SN. The 95th percentile of R2* (hereafter, SN-AI95) was compared according to infarct location with mixed linear regression models. We also conducted voxel-based comparisons of R2* and identified individual infarcted vo...

11 November 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
JBJean-Luc Brun
Jean-Luc Brun
DLDéborah Letoffet
Déborah Letoffet
MMMarion Marty
Marion Marty
RGRomain GRIFFIER
Romain GRIFFIER
XAXavier Ah-Kit
Xavier Ah-Kit
IGIsabelle Garrigue
Isabelle Garrigue

18 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GWGriffin M. Weber
Griffin M. Weber
Chuan HongChuan Hong
Chuan Hong
NPNathan P Palmer
Nathan P Palmer
PAPaul Avillach
Paul Avillach
SMShawn N Murphy
Shawn N Murphy
GBGabriel A Brat
Gabriel A Brat
Objectives: To perform an international comparison of the trajectory of laboratory values among hospitalized patients with COVID-19 who develop severe disease and identify optimal timing of laboratory value collection to predict severity across hospitals and regions. Design: Retrospective cohort study. Setting: The Consortium for Clinical Characterization of COVID-19 by EHR (4CE), an international multi-site data-sharing collaborative of 342 hospitals in the US and in Europe. Participants: Patients hospitalized with COVID-19, admitted before or after PCR-confirmed result for SARS-CoV-2. Primary and secondary outcome measures: Patients were categorized as “ever-severe” or “never-severe” using the validated 4CE severity criteria. Eighteen laboratory tests associated with poor COVID-19-related outcomes were evaluated for predictive accuracy by area under the curve (AUC), compared between the severity categories. Subgroup analysis was performed to validate a subset of laboratory values as predictive of severity against a published algorithm. A subset of laboratory values (CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin) was compared between North American and European sites for severity prediction. Results: Of 36,447 patients with COVID-19, 19,953 (43.7%) were categorized as ever-severe. Most patients (78.7%) were 50 years of age or older and male (60.5%). Longitudinal trajectories of CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin showed association with disease severity. Significant differences of laboratory values at admission were found between the two groups. With the exception of D-dimer, predictive discrimination of laboratory values did not improve after admission. Sub-group analysis using age, D-dimer, CRP, and lymphocyte count as predictive of severity at admission showed similar discrimination to a published algorithm (AUC=0.88 and 0.91, respectively). Both models deteriorated in predictive accuracy as the disease progressed. On average, no difference in severity prediction was found between North American and European sites. Conclusions: Laboratory test values at admission can be used to predict severity in patients with COVID-19. Prediction models show consistency across international sites highlighting the potential generalizability of these models.

18 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GBGabriel A Brat
Gabriel A Brat
GWGriffin M. Weber
Griffin M. Weber
NGNils Gehlenborg
Nils Gehlenborg
PAPaul Avillach
Paul Avillach
NPNathan P Palmer
Nathan P Palmer
IKIsaac S Kohane
Isaac S Kohane
We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across 5 countries ( www.covidclinical.net ). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on comorbidities and temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions.

4 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BMBertrand Moal
Bertrand Moal
AOArthur ORIEUX
Arthur ORIEUX
TFThomas Ferté
Thomas Ferté
ANAntoine Neuraz
Antoine Neuraz
GBGabriel A. Brat
Gabriel A. Brat
VJVianney Jouhet
Vianney Jouhet
Purpose: In young adults (18 to 49 years old), investigation of the acute respiratory distress syndrome (ARDS) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been limited. We evaluated the risk factors and outcomes of ARDS following infection with SARS-CoV-2 in a young adult population. Methods: A retrospective cohort study was conducted between January 1st, 2020 and February 28th, 2021 using patient-level electronic health records (EHR), across 241 United States hospitals and 43 European hospitals participating in the Consortium for Clinical Characterization of COVID-19 by EHR (4CE). To identify the risk factors associated with ARDS, we compared young patients with and without ARDS through a federated analysis. We further compared the outcomes between young and old patients with ARDS. Results: Among the 75,377 hospitalized patients with positive SARS-CoV-2 PCR, 1001 young adults presented with ARDS (7.8% of young hospitalized adults). Their mortality rate at 90 days was 16.2% and they presented with a similar complication rate for infection than older adults with ARDS. Peptic ulcer disease, paralysis, obesity, congestive heart failure, valvular disease, diabetes, chronic pulmonary disease and liver disease were associated with a higher risk of ARDS. We described a high prevalence of obesity (53%), hypertension (38%- although not significantly associated with ARDS), and diabetes (32%). Conclusion: Trough an innovative method, a large international cohort study of young adults developing ARDS after SARS-CoV-2 infection has been gather. It demonstrated the poor outcomes of this population and associated risk factor.